Business Context and Reporting Period
This Form 8-K filing by N2OFF, Inc. (NITO) covers events occurring on September 25, 2025. The company, incorporated in Delaware with principal offices in Israel, is an emerging growth company listed on The Nasdaq Capital Market. The report details the results of a Special General Meeting of stockholders held on this date.
Key Financial Metrics
The filing does not provide specific financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance actions and stockholder voting results.
Material Changes and Corporate Actions
- Reverse Stock Split: The company effected a 1-for-35 reverse stock split on September 22, 2025. All share counts in the voting results are presented on a pre-split basis.
- Shareholder Approval of Acquisition: Stockholders approved the acquisition of MitoCareX Bio Ltd., a private Israeli company focused on drug discovery for resistant cancers (including pancreatic and non-small cell lung cancer). The deal involves issuing shares equal to or exceeding 20% of the company's outstanding common stock.
- Warrant Issuance Approval: Stockholders approved the issuance of 1,850,000 shares of Common Stock upon the exercise of a warrant held by L.I.A. Pure Capital Ltd.
- Future Reverse Split Authorization: Stockholders authorized the Board to effect a future reverse stock split at a ratio between 1-for-2 and 1-for-150 within one year, without further stockholder approval.
Voting Results Summary
| Proposal | For | Against | Abstain | Broker Non-Votes |
|---|---|---|---|---|
| Acquisition of MitoCareX | 11,687,364 | 197,347 | 18,579 | 6,672,619 |
| Reverse Stock Split Authorization | 15,703,054 | 2,172,381 | 700,474 | N/A |
| Warrant Shares Issuance | 10,498,529 | 294,575 | 1,110,186 | 6,672,619 |
| Adjournment Authorization | 17,130,615 | 798,625 | 646,669 | N/A |
As of the record date (August 1, 2025), there were 33,356,412 shares outstanding. Approximately 55.68% of outstanding shares were represented at the meeting, constituting a quorum.
Outlook, Risks, and Contingencies
The filing indicates a strategic pivot toward oncology drug discovery through the acquisition of MitoCareX. The company has secured stockholder approval to issue significant equity (over 20% of outstanding shares) to complete this transaction. The filing does not explicitly detail specific risks or contingencies beyond the standard requirement for stockholder approval of significant equity issuances under Nasdaq rules.
Investor Verification Checklist
- Verify the final post-split share count and the exact number of shares to be issued to MitoCareX shareholders.
- Review the full text of the Securities Purchase and Exchange Agreement (dated February 25, 2025, as amended) for deal terms and conditions.
- Confirm the specific terms of the warrant issued to L.I.A. Pure Capital Ltd. and the exercise price.
- Monitor the Board's decision on the exact ratio for the future reverse stock split (1-for-2 to 1-for-150 range).
- Assess the dilution impact of the MitoCareX acquisition and warrant exercise on existing shareholders.